Literature DB >> 15028852

Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy.

N Joss1, C Ferguson, C Brown, C J Deighan, K R Paterson, J M Boulton-Jones.   

Abstract

BACKGROUND: Diabetic nephropathy is the single most common cause of chronic renal failure requiring dialysis. Effective treatment exists, but no clinical audit or large trial has reduced the rate of loss of renal function as effectively as in small groups of intensively managed patients. AIM: To determine the effect of intensive vs. standard medical management on the rate of progression of renal failure in patients with diabetic nephropathy.
DESIGN: Prospective randomized controlled study.
METHODS: Patients with type 2 diabetes and nephropathy were randomly allocated to an intensive group (n = 47) or control group (n = 43). Treatment targets were the same for both groups, but the intensive group were seen as often as required to meet the targets; controls were seen at their normal clinics. The primary end-point was the rate of progression of renal disease in the second year.
RESULTS: The groups were well matched at baseline. During follow-up, the intensive group had lower mean SBP, DBP and cholesterol. Median rate of progression of renal failure in the intensive group fell from 0.44 ml/min/month in the first year to 0.14 ml/min/month in the second year, compared to 0.49 ml/min/month and 0.53 ml/min/month in the control group (p = 0.04 for second year). Patients in the intensive group spent significantly less time in hospital. DISCUSSION: Intensive treatment slowed progression of renal disease within 2 years in patients with established diabetic nephropathy. Mean creatinine clearance at the start of the trial was 55 ml/min, so assuming that the rates of progression achieved at the end of the second year persisted, onset of dialysis would be delayed by 20 years in the intensive group compared with the control group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028852     DOI: 10.1093/qjmed/hch039

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

1.  Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.

Authors:  Peter Noel Van Buren; Beverley Adams-Huet; Robert Daniel Toto
Journal:  J Investig Med       Date:  2010-12       Impact factor: 2.895

2.  Clinic versus home blood pressure measurements in patients with CKD.

Authors:  Robert Stanton
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

3.  Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  Julie Ménard; Hélène Payette; Jean-Patrice Baillargeon; Pierre Maheux; Serge Lepage; Daniel Tessier; Jean-Luc Ardilouze
Journal:  CMAJ       Date:  2005-11-17       Impact factor: 8.262

Review 4.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

5.  Efficacy of a disease management program focused on acquisition of self-management skills in pre-dialysis patients with diabetic nephropathy: 24 months follow-up.

Authors:  Kana Kazawa; Yae Takeshita; Noriaki Yorioka; Michiko Moriyama
Journal:  J Nephrol       Date:  2014-09-24       Impact factor: 3.902

6.  Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].

Authors:  Arjan D van Zuilen; Ingeborgh van der Tweel; Peter J Blankestijn; Michiel L Bots; Marjolijn van Buren; Marc A G J ten Dam; Karin A H Kaasjager; Peter J G van de Ven; Gerald Vervoort; Louis-Jean Vleming; Gerry Ligtenberg; Jack F M Wetzels
Journal:  Trials       Date:  2006-03-30       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.